MX390927B - Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina. - Google Patents
Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.Info
- Publication number
- MX390927B MX390927B MX2018000023A MX2018000023A MX390927B MX 390927 B MX390927 B MX 390927B MX 2018000023 A MX2018000023 A MX 2018000023A MX 2018000023 A MX2018000023 A MX 2018000023A MX 390927 B MX390927 B MX 390927B
- Authority
- MX
- Mexico
- Prior art keywords
- particles
- virus
- gag protein
- bovine immunodeficiency
- immunodeficiency virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/866—Baculoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562188084P | 2015-07-02 | 2015-07-02 | |
| PCT/US2016/040838 WO2017004586A1 (en) | 2015-07-02 | 2016-07-01 | Recombinant virus like particles using bovine immunodeficiency virus gag protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000023A MX2018000023A (es) | 2018-08-15 |
| MX390927B true MX390927B (es) | 2025-03-21 |
Family
ID=57609369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000023A MX390927B (es) | 2015-07-02 | 2016-07-01 | Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11576965B2 (https=) |
| EP (1) | EP3316906A4 (https=) |
| JP (2) | JP6978079B2 (https=) |
| KR (1) | KR20180032586A (https=) |
| CN (2) | CN115927212A (https=) |
| BR (1) | BR112018000037A2 (https=) |
| CA (1) | CA2991213A1 (https=) |
| EA (1) | EA201890187A1 (https=) |
| MA (1) | MA42312A (https=) |
| MX (1) | MX390927B (https=) |
| PE (1) | PE20180771A1 (https=) |
| RU (2) | RU2757723C2 (https=) |
| WO (1) | WO2017004586A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42312A (fr) * | 2015-07-02 | 2018-05-09 | Medigen Inc | Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine |
| CN112279900A (zh) * | 2020-12-30 | 2021-01-29 | 乾元浩生物股份有限公司 | H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用 |
| CN113403343A (zh) * | 2021-04-30 | 2021-09-17 | 吉林大学 | 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备 |
| CN113398259A (zh) * | 2021-04-30 | 2021-09-17 | 吉林大学 | 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004042001A2 (en) | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| DE60335139D1 (de) * | 2002-05-17 | 2011-01-05 | Univ Emory | Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US8506967B2 (en) | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
| WO2008005777A2 (en) * | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| WO2008094200A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US20100247574A1 (en) | 2007-02-21 | 2010-09-30 | Kutub Mahmood | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs |
| SG10201509679XA (en) | 2007-05-29 | 2015-12-30 | Christopher B Reid | Methods for production and uses of multipotent cell populations |
| EP2175882A4 (en) * | 2007-07-19 | 2011-11-30 | Novavax Inc | VARICELLA ZOSTER VIRUS VIRUS LIKE PARTICLES (VLP) AND ANTIGENE |
| WO2011087839A1 (en) * | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| AU2011258165B2 (en) * | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| WO2012122858A1 (zh) * | 2011-03-17 | 2012-09-20 | 中国科学院上海巴斯德研究所 | 一种利用果蝇细胞生产病毒样颗粒的方法及应用 |
| WO2015066715A1 (en) * | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
| MA42312A (fr) * | 2015-07-02 | 2018-05-09 | Medigen Inc | Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine |
-
2016
- 2016-07-01 MA MA042312A patent/MA42312A/fr unknown
- 2016-07-01 WO PCT/US2016/040838 patent/WO2017004586A1/en not_active Ceased
- 2016-07-01 EP EP16818931.4A patent/EP3316906A4/en active Pending
- 2016-07-01 CN CN202210931466.8A patent/CN115927212A/zh active Pending
- 2016-07-01 RU RU2020125098A patent/RU2757723C2/ru active
- 2016-07-01 CN CN201680050161.9A patent/CN108348596B/zh active Active
- 2016-07-01 JP JP2018520386A patent/JP6978079B2/ja active Active
- 2016-07-01 EA EA201890187A patent/EA201890187A1/ru unknown
- 2016-07-01 KR KR1020187003292A patent/KR20180032586A/ko not_active Ceased
- 2016-07-01 PE PE2018000003A patent/PE20180771A1/es not_active Application Discontinuation
- 2016-07-01 MX MX2018000023A patent/MX390927B/es unknown
- 2016-07-01 US US15/741,443 patent/US11576965B2/en active Active
- 2016-07-01 RU RU2018103757A patent/RU2734118C2/ru active
- 2016-07-01 CA CA2991213A patent/CA2991213A1/en active Pending
- 2016-07-01 BR BR112018000037-0A patent/BR112018000037A2/en active IP Right Grant
-
2020
- 2020-09-14 JP JP2020153664A patent/JP2020198893A/ja not_active Withdrawn
-
2023
- 2023-01-12 US US18/153,667 patent/US12303560B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115927212A (zh) | 2023-04-07 |
| RU2734118C2 (ru) | 2020-10-13 |
| WO2017004586A1 (en) | 2017-01-05 |
| US20180369364A1 (en) | 2018-12-27 |
| MA42312A (fr) | 2018-05-09 |
| US20230310579A1 (en) | 2023-10-05 |
| PE20180771A1 (es) | 2018-05-07 |
| MX2018000023A (es) | 2018-08-15 |
| JP6978079B2 (ja) | 2021-12-08 |
| EP3316906A1 (en) | 2018-05-09 |
| KR20180032586A (ko) | 2018-03-30 |
| US12303560B2 (en) | 2025-05-20 |
| CN108348596B (zh) | 2022-08-23 |
| RU2757723C2 (ru) | 2021-10-21 |
| JP2020198893A (ja) | 2020-12-17 |
| US11576965B2 (en) | 2023-02-14 |
| EP3316906A4 (en) | 2019-01-02 |
| RU2020125098A3 (https=) | 2020-12-11 |
| CA2991213A1 (en) | 2017-01-05 |
| JP2018525028A (ja) | 2018-09-06 |
| CN108348596A (zh) | 2018-07-31 |
| HK1259067A1 (zh) | 2019-11-22 |
| BR112018000037A2 (en) | 2018-09-04 |
| EA201890187A1 (ru) | 2018-06-29 |
| RU2020125098A (ru) | 2020-09-04 |
| RU2018103757A (ru) | 2019-08-05 |
| RU2018103757A3 (https=) | 2019-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| CY1122705T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας,και μεθοδοι χρησης τους | |
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| MA39803A (fr) | Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation | |
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| CY1125681T1 (el) | Εμβολια κατα του ιου της γριπης και χρησεις αυτων | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| MX378905B (es) | Pestivirus. | |
| MY179251A (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| MX390418B (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso. | |
| MX390927B (es) | Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina. | |
| MX2021003392A (es) | Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados. | |
| ZA202003070B (en) | Lassa vaccine | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| PH12018501183A1 (en) | Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same | |
| EA201892085A1 (ru) | Новые белки, полученные из альфа-1-микроглобулина, и их применение | |
| EP4674985A3 (en) | Compositions and methods related to characterizing proviral reservoirs | |
| EA201992054A1 (ru) | Циклические сульфамидные соединения и способы их применения | |
| EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| CA3009928A1 (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |